Association of Time of Day When Endovascular Therapy for Stroke Starts and Functional Outcome

Steven D Hajdu MD, Johannes Kaesmacher MD, Prof Patrik Michel MD, Gaia Sirimarco MD, Jean-Francois Knebel, Bruno Bartolini MD, Christoph C Kurmann, Francesco Puccinelli MD, Pascal J Mosimann MD, Christophe Bonvin MD, Prof Marcel Arnold, Julien Niederhäuser MD, Ashraf Eskandari, Pasquale Mordasini MD, Prof Jan Gralla MD, Prof Urs Fischer MD, Prof Guillaume Saliou MD

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Neurology® Published Ahead of Print articles have been peer reviewed and accepted for publication. This manuscript will be published in its final form after copyediting, page composition, and review of proofs. Errors that could affect the content may be corrected during these processes.
Objective: To investigate the association between EVT start time in acute ischemic stroke (AIS) and mid-term functional outcome.
Methods: This retrospective cohort study included all AIS cases treated with EVT from two stroke center registries from January 2012 to December 2018. The primary outcome was the score on the modified Rankin Scale (mRS) and the utility-weighted mRS (uw-mRS) at 90 days. A proportional odds model was used to calculate the common odds ratio as a measure of the likelihood that the intervention at a given EVT start time would lead to lower scores on the mRS (shift analysis).

Results: One thousand five hundred fifty-eight cases were equally allotted into twelve EVT-start-time periods. The primary outcome favored EVT start times in the morning at 08:00-10:20 and 10:20-11:34 (common odds ratio (OR), 0.53; 95% confidence interval (CI), 0.38 to 0.75; P<0.001; OR, 0.62; 95% CI, 0.44 to 0.87; P=0.006, respectively), while it disfavored EVT start times at the end of the working day at 15:55-17:15 and 18:55-20:55 (OR, 1.47; 95% CI, 1.03 to 2.09; P=0.034; OR, 1.49; 95% CI, 1.03 to 2.15; P=0.033). Symptom onset-to-EVT start time was significantly higher and use of IV t-PA significantly lower between 10:20-11:34 (P<0.004 and P=0.012, respectively).

Conclusion: EVT for AIS in the morning leads to better mid-term functional outcome, while EVT at the end of the work day leads to poorer mid-term functional outcome. Neither difference in baseline factors, standard workflow and technical efficacy metrics could be identified as potential mediators of this effect.
Introduction

Research on occupational accidents indicates that the risk of accidents while working increases as a function of number of hours at work. Hänecke and colleagues reported an exponential increase in occupational accidents after the ninth hour of work. Although most countries officially define the workday as eight hours, many doctors experience working hours well-beyond nine hours due to the need of 24-hour patient-care coverage. Neurointerventionists and the rest of the stroke management team are currently feeling the effects of the changes in acute ischemic stroke (AIS) management, due in part to the mounting level of evidence from several large randomized controlled studies since 2015 that demonstrated the value of endovascular therapy (EVT) for first-line and delayed treatment. The significant increase in the number of EVT-eligible patients has proportionally increased the emergency case-load for the neurointerventionists as well as the whole support staff in the stroke unit which extends the number of hours at work and could be a potential source of fatigue. The need to examine the effects of doctor fatigue on the mid-term outcome of treated patients was recognized and reported in the literature. Current data on mid-term functional outcome in patients treated during work hours versus after hours is limited requiring more robust studies to elucidate the effects on patients treated at different times of the day. We sought to investigate the association between EVT performed by presumed fatigued neurointerventionists and the stroke unit staff after standard working hours and the mid-term neurological outcome in treated patients.
Methods

Patient population:

We used two institutional databases, the acute stroke registry and analysis of Lausanne (ASTRAL) from Lausanne University hospital, Switzerland and the stroke registry from University Hospital of Bern, Bern, Switzerland; to retrospectively include all adult AIS patients who received EVT, either as thromboaspiration and/or mechanical thrombectomy according to institutional guidelines, from January 2012 to December 2018. For patient selection, we used the following inclusion criteria: AIS secondary to a large vessel intracranial occlusion, CT-based multimodal imaging performed within 24 hours of last proof of good health showing occlusion of an intracranial vessel amendable to EVT, brain angiography of good quality showing results following recanalization. Extracranial internal carotid artery occlusion or symptomatic stenosis without intracranial occlusion were excluded.

Both hospitals feature a comprehensive stroke center accredited by the Swiss Federation of Clinical Neurosocieties Swiss Stroke Committee mainly based on recommendations of the Swiss Stroke Society and European Stroke Organisation.

Stroke team composition was similar among both centers and included an onsite neurologist trainee, on-call stroke attending neurologist, onsite attending anesthesiologist, and on-call attending interventional neurologist at all times including standard working hours, nighttime, and weekends. Imaging protocol and EVT criteria were based on local institutional guidelines and were applied in the same way regardless of admission day or time. For the University Hospital of Bern, MRI is performed during night and daytime and there are no differences in its availability.

Indications for EVT are standardized according to an institutional operating procedure scheme. For Lausanne University Hospital, a dedicated emergency MR imager is available 24 hours a day, 7 days a week. It prioritizes stroke cases and there are no differences in its availability during nighttime and weekends relative to daytime.
Indications for EVT are identical to those mentioned in the operating procedures of University Hospital of Bern. Transfer patients were generally not re-imaged unless transfer times were greater than 1.5 hours or the patient severely deteriorated after thrombolysis. In these two situations, perfusion-CT/MRI was repeated prior to EVT. Both centers have between four and six interventional neuroradiologists in order to provide one on-call physician per center working in 24-hour shifts covering five to seven days per month. Approximately five EVTs are performed at Lausanne University and seven at University Hospital of Bern per week. During EVT, operators work almost exclusively independently with one angiography-suite technician working in eight-hour shifts providing technical and material support. Endovascular trainees are oftentimes present during EVT, but do not participate as primary or secondary operators. Finally, a wide array of stent retriever devices are used in these centers to perform EVT including, but not limited to Trevo (Stryker, Kalamazoo, Michigan, USA), Solitaire (Medtronic, Irvine, California, USA), Embotrap (Cerenovus, Galway, Ireland), Catch (Balt Extrusion, Montmorency, France) and Tiger (Rapid Medical, Yokneam, Israel).

Data collection:
Stroke-time onset and/or last time seen without symptoms, groin puncture-time and recanalization time were recorded for each patient. The EVT start time was considered the operator’s groin-puncture-time. A disproportionate number of EVTs were performed during normal working hours, making analysis at fixed time intervals with unequal cohort sizes a potential source of bias. As a result, patients were divided into twelve cohorts containing the same number of patients according to EVT start time, beginning at 08:00, the start of the work day, until 07:59 the following day. Time periods varied between cohorts, with those during the day shorter and those at night longer. To perform a multivariate analysis and eliminate confounding factors,
the following patient characteristics were recorded: age, sex, atrial fibrillation, smoking, diabetes, hypertension, and hyperlipidemia, as well as stroke characteristics including, National Institutes of Health Stroke Scale (NIHSS) score at admission, pre-stroke modified Rankin Scale score (mRS), Alberta stroke program early CT score (ASPECTS), occlusion site, pre-stroke utility-weighted modified Rankin Scale score (uw-mRS), concomitant iv t-PA (tissue plasminogen activator), Trial of ORG 10172 in Acute Stroke Treatment (TOAST) mechanism type, symptom onset-to-EVT start time, admission-to-EVT start time and occlusion site; defined as: 1-Large-artery atherosclerosis, 2-Cardioembolism, 3-Small-vessel occlusion, 4-Stroke of other determined aetiology, and 5-Stroke of undetermined etiology. The EVT characteristics reported included the following: modified treatment in cerebral ischemia (mTICI) score, number of EVT passes, symptomatic intracranial haemorrhage (sICH), and uw-mRS at 90 days post-EVT.

Primary and secondary outcomes:
The primary outcome of the study was the score on the modified Rankin scale at 90 days after EVT, which was assessed by trained personnel who were unaware of the EVT start time. The modified Rankin scale is a graded interval scale (range, 0 [no symptoms] to 6 [death]) for the assessment of neurologic functional disability. Secondary outcomes included EVT start-to-recanalization interval time, mTICI score, number of EVT passes, and rate of sICH.

Statistical analyses:
Our analyses were performed to detect a shift in the distribution of scores on the modified Rankin scale at 90 days between each EVT time start time, with scores of 5 (bedbound with severe disability) and 6 (death) combined due to comparable patient-centered outcome and with the assumption that the differential effect would lead to a
common odds ratio (indicating the odds of improvement of 1 point on the modified Rankin scale) of 0.6 for positive effects and 1.4 for negative effects. Comparisons of baseline characterisitics between cohorts were conducted using a one-way ANOVA for continuous variables of interest (age, NIHSS at admission, onset-to-EVT start time, number of EVT passes, baseline, EVT start-to-recanalization time, and uw-mRS at 90 days). Chi-square analysis was conducted for categorical variables of interest (atrial fibrillation, hypertension, smoking, diabetes, hyperlipidaemia, intravenous t-PA, TOAST, baseline, mTICI, and sICH). Continuous variables were presented using mean and interquartile range (IQR). Categorical variables were presented as frequencies with percentages. Significance was set at $p <0.05$.

Detection of statistically significant variables was performed by a univariate analysis using an unpaired $t$-test comparing one cohort to all other reference cohorts, then subsequently repeated for other cohorts. Significance was set at $p <0.05$.

Adjusted estimates of effect were selected according to clinical relevance and adjusted for age, symptom onset-to-EVT start time, age, NIHSS score, mTICI score, hypertension, and pre-stroke modified Rankin Scale score. The assessment of heterogeneity of EVT start time effect was performed with the inclusion of multiplicative interaction terms. Significance was set at $p <0.05$.

Statistical analyses were performed using Anaconda version 5.3.1 (Anaconda, Austin, Texas, United States) for Python 2.7 (PSF, Delaware, United States) linked via module Rpy2 with R version 3.5.1ci (R Foundation, Vienna, Austria). For the primary endpoint, an ordinal multivariate logistic regression was performed with proportional odds ratio. To perform it, a Vector Generalized Linear and Additive Models (VGLM/VGAM) library was used in R. The confounding factors added into the
model were selected by clinical relevance. Non-collinearity was verified using
tolerance metric in the R package ‘olsrr.’ All variables had a tolerance greater than
0.2 with the lowest tolerance calculated at 0.23. This confirmed our clinical
assumption of no collinearity between variables.

Standard Protocol Approvals, Registrations, and Patient Consents:
The study was approved by the local institutional review board of each hospital under
the auspices of the Swiss ethics committees for research involving humans
(Swissethics). No informed consent was required according to the legislation.

Data Availability:
Individual deidentified participant data, related documents such as study protocol, and
statistical analysis will be shared on request from any qualified investigator for three
years after the date of publication.

Results
A total of 1,574 EVT consecutive procedures meeting selection criteria were selected
for review, with 991 cases derived from University Hospital of Bern of which 660
were direct presentations (66%) and 581 from Lausanne University Hospital of which
490 were direct presentations (83%). Sixteen cases were lost on follow-up as no
information on mid-term functional neurological status was available. The 1,558
cases available for analysis were distributed according to EVT start time into equal
size patient-cohort time periods, each containing 127 to 131 patients. The cohorts
were as follows: 08:00-10:20, 10:20-11:34, 11:34-12:40, 12:40-13:37, 13:37-14:41,
14:41-15:55, 15:55-17:15, 17:15-18:55, 18:55-20:55, 20:55-22:57, 22:57-02:07 and
02:07-07:58
Demographics, cardiovascular risk factors, and stroke characteristics:

A description of the demographics and cardiovascular risk factors for each patient cohort is shown in table 1. In summary, no inhomogeneity was detected in patient cohorts relating to demographics and cardiovascular risk factors with the exception of age; a small, yet statistically significant younger population was observed in the morning 08:00-10:20 cohort (P=0.002). The absolute difference of mean age between patients in this cohort relative to the mean of all patients included in the study was 3.5 years. Additionally, fewer patients in this cohort were hypertensive (P=0.025). A description of stroke characteristics for each patient cohort is shown in table 2. Stroke characteristics were similarly homogenous with the exception of symptom onset-to-EVT start time, IV t-PA use and admission-to-EVT start time. Onset-to-EVT start time was significantly longer between 10:20-11:34 and 02:07-07:58, while significantly shorter between 20:55-22:57 and 22:57-02:07 (P=0.004). Intravenous t-PA was used less frequently between 10:20-11:34 and 02:07-07:58 (P=0.012). Admission-to-EVT start time was significantly longer between 02:07-07:58. A description of stroke occlusion site is shown in table 3. Distribution of stroke occlusion site was homogenous among all cohorts.

Primary endpoint, EVT-start time and mid-term functional outcome:

Table 4 describes the univariate and multivariate analyses investigating the relationship between the EVT-start time and mRS, uw-mRS and mortality at 90 days. Analysis of the primary end point showed a common odds ratio (indicating the odds of improvement of 1 point on the modified Rankin scale) of 0.53 (95% confidence interval [CI], 0.38 to 0.75, P<0.001) and of 0.62 (95% CI, 0.44 to 0.87, P=0.006) favoring EVT with start times in the morning at 08:00-10:20 and 10:20-11:34 as well as 1.47 (95% CI, 1.03 to 2.09, P=0.034) and 1.49 (95% CI, 1.03 to 2.15, P=0.033) at 15:55-17:15 and 18:55-20:55, respectively, disfavoring EVT at start times at the end
of the work day. Figure 1 shows the effect size in the primary end point across all EVT start time cohorts. There was a higher uw-mRS at 90 days signifying better functional outcome in patients with EVT performed between 08:00-10:20 (5.9, 95% CI, 3.3 to 9.1, p<0.001) as well as EVT performed between 10:20-11:34 (5.2, 95% CI, 0.0 to 9.1, p=0.008) and significantly lower uw-mRS signifying poorer functional outcome in patients treated at 15:55-17:15 (5.0, 95% CI, 0.0 to 8.4, p=0.017) (P=0.017). Figure 2 depicts the uw-mRS at 90 days as a function of time-period cohort for both stroke centres. Similar trends in functional outcome are observed in each stroke centre.

The proportion of patients with a modified Rankin score of 0 to 2 at 90 days was 37.6% and 37.2% when EVT start times were between 08:00-10:20 and 10:20-11:34, respectively, while only 22.5% and 19.0% for EVT start times at 15:55 and 18:55-20:55. Mortality at 90 days was lower in the morning in 12.8% patients with EVT start time at 08:00-10:20 (OR: 0.52; 95% CI, 0.28 - 0.90; P = 0.028) and higher in at the end of the workday in 32.5% patients when EVT start times were 15:55-17:15 (OR: 1.78; 95% CI, 1.21 - 2.79; P = 0.013)

Secondary endpoints, EVT procedural characteristics:

Table 5 describes the univariate analysis of EVT characteristics in all time-period cohorts. In summary, mTICI score, number of EVT passes, presence of sICH and EVT start-to-recanalization time were not significantly different.

Discussion

The main finding of the present study is that mid-term functional outcome and mortality after EVT in AIS varied according to the start time of thrombectomy. EVT performed in the morning, 08:00-10:15, yielded good functional outcomes, whereas EVT performed after the ninth hour of work, 15:55-17:15, lead to poorer functional
outcomes. Surprisingly, outcome from EVT performed at nighttime is not significantly worse than EVT performed during the day. The difference observed does not seem to be caused neither by differences in baseline characteristics nor due to difference in standard measures of interventional efficacy and safety at different time points.

Endovascular therapy is a procedure requiring a high degree of vigilance and reflex, developed after several years of specialized training that may become impaired due to extended working hours. Patients admitted out of normal work hours are less likely to be managed according to current operational guidelines leading to poorer short-term outcomes than those admitted during normal work hours. We hypothesized that EVT performed outside of the workday or at night would lead to poorer mid-term functional outcome because of doctor fatigue. The link between fatigue and performance remains controversial, with some studies failing to demonstrate any correlation between extended working hours worked and doctor performance or safety outcomes. A systematic literature review by Gates and colleagues suggests that evidence for possible association of doctor fatigue with performance is varied in part because of the use of heterogeneous outcome measurements. In stroke management, the outcomes of interest are mid-term functionality graded on the mRS and uw-mRS, a patient-centred scale that measures benefit of a given intervention to the patient. We studied effect on mRS as a function of EVT-start time. Assuming that the on-call neurointerventionist begins his workday between 07:00 and 08:00, our study suggests that at the start of the workday, between 08:00-10:31, technical performance is optimal in a rested and vigilant doctor leading to the significantly higher uw-mRS at 90 days, or better mid-term functional outcome observed. However, the analyses of the secondary endpoints measuring technical performance did not reveal higher rates of complete recanalization, fewer numbers of EVT passes,
faster procedure times or lower rates of sICH. Notably, in this cohort, symptom onset-to-EVT start times were significantly longer and on average beyond 4.5 hours. This may suggest that many patients in this cohort met the stricter EVT requirements and thus had relatively better collateral circulation and smaller core infarct sizes, which could be a potential source of selection bias. Any possible inhomegeinity between cohorts cannot be corroborated because these two stroke characterisitcs were not recorded in the majority of patients in the two institutional databases used in this study. We hypothesize that in the morning cohorts, an increased number of stroke patients of unknown onset with limited infarct core size due to good collateralization were selected for EVT and thus had a higher probability of favorable mid-term functional outcome. These patients were statistically younger than other cohorts thus had better leptomeningeal collateral circulation and better hemodynamic variables with hypothetically small core size volumes. This cannot be substantiated in this study because infarct volume size was not available for analysis in this dataset.\textsuperscript{28,29} Also, only 66.4% patients at 08:00-10:15 were hypertensive compared to a frequency of 74.7% for all groups. While concomitant hypertension in AIS is associated with poorer outcome and therefore could in part explain better outcome in the morning cohorts, we do not observe a statistically poorer outcome in cohorts with higher frequency hypertension. Additionally, any inhomogeneity in rates of hypertension among the cohorts cannot solely explain, according to the applied statistical model, the difference in mid-term functional outcome.\textsuperscript{30} Moreover, this could also indicate that a large number of patients were deemed unsuitable, but possibly could of benefitted from EVT.

Conversely, EVT\textsuperscript{s} performed between 15:55-17:15, after a nine-hour workday, were associated with higher mRS at 90 days or poorer mid-term functional functional outcome. Although, our multivariate analysis showed significantly higher mRS at 90 days, intermediate outcome measurements that have predictive effects on mid-term
functional outcome, like mTICI, number of EVT passes, rate of sICH were not significantly altered in this time period.\cite{31-33} Moreover, EVT start-to-recanalization time, a measure of technical skill, and rapidity, was not significantly different between time-period cohorts. We therefore hypothesize that other factors independent of doctor fatigue, such as stroke team shift changes or hampered performance from other collaborators such as emergency neurologist or support staff in the stroke unit, may contribute to poor functional outcome. Figure 3 shows the work shifts for interventional neuroradiology, stroke unit and emergency neurology physicians at both centers. Additionally, the observed outcome decline between 15:55-17:15 was only transient, with values of uw-mRS at 90 days actually increasing after 17:15, at the end of the standard work day in our two hospitals. Admission-to-groin puncture delay were significantly longer at night, which has been previously reported.\cite{34,35} Corroborating the findings of the MR CLEan Registry, this delay was not appreciable in our analysis regarding clinical outcome. We conjecture that working conditions for EVT paradoxically improves during the evening or night and may maintain good technical performance and offset fatigue partially because of less work burden and/or distractions. Studies on work-related injuries as a function of the number of hours worked, showed a transient, yet significant increase after the ninth hour of work, but a non significant risk thereafter or at nighttime.\cite{4,36} The results of this study show similar findings regarding functional outcome and highlights similar trends in both stroke centres included in this study. Finally, the repercussions of the burgeoning demand for EVT due to recent paradigm shifts of AIS management on neurointerventionists and the stroke unit staff remains controversial.\cite{25} Previously, AIS stroke management was limited to IVT, requiring knowledge but not depending on technical skill. Nowadays, the complexities involved in EVT during AIS management, poses challenges to neurointerventionists,
anaesthetists, and stroke unit staff faced with increasing caseload, extended working hours, and more on-call duties. Our data show differences in outcome warranting further investigation of current workplace conditions for EVT in AIS on patient outcome.

Limitations:
One of the weaknesses of this study is that many of the confounding variables cannot be controlled in the analyses, such as variability in a doctor’s skill, training level or overall stroke-unit performance. For example, interruptions of activity related to shift changes, patient transferring, and diagnostic exams during the day may decrease the amount of time for direct patient care in certain cohorts leading to adverse effects prior to or following EVT. Any potential difference may also be observed between the hospitals included in this study as Lausanne University Hospital performs fewer EVT than University Hospital of Bern. Nevertheless, the subgroup analysis of uwmRS at 90 days for each hospital reveals similar trends as a function of EVT-start time, most notably at 15:54-17:15. Moreover, the addition of center variables, such as hospital site or weekday versus weekend, to the logistic regression did not affect results. Additionally, perfusion imaging data and infarct core size score were not available for analysis and inhomogeneity in these characteristics among the cohorts may explain differences in clinical outcome. Other limitations include the fact that this study is retrospective and includes AIS patients treated by EVT from 2012, an era when EVT was less standardized.

Conclusion
EVT for AIS patients performed in the morning between 08:00-10:20 leads to better mid-term functional outcome at 90 days, despite having a statistically longer symptom onset-to-EVT start time delay, while EVT performed at the end of the
working day, between 15:54-17:15, leads to poorer neurological outcome. Additional prospective studies data are required to support our findings and further analysis regarding causal relation are warranted.

Appendix 1: Authors

| Name                  | Location                               | Contribution                                                                 |
|-----------------------|----------------------------------------|------------------------------------------------------------------------------|
| Steven D Hajdu        | Lausanne University Hospital,          | Design and conceptualized study; data analysis; drafted and revised the      |
|                       | Lausanne, Switzerland                  | manuscript for intellectual content                                         |
| Johannes Kaesmacher   | University Hospital of Bern, Bern,     | Design and conceptualized study; data analysis; drafted and revised the      |
|                       | Switzerland                            | manuscript for intellectual content                                         |
| Name                        | Institution                        | Role                                                                 |
|-----------------------------|-------------------------------------|----------------------------------------------------------------------|
| Patrik Michel               | Lausanne University Hospital, Lausanne, Switzerland | Major role in acquisition of data; interpreted the data               |
| Gaia Sirimarco             | Lausanne University Hospital, Lausanne, Switzerland | Interpreted the data; revised the manuscript for intellectual content |
| Jean-Francois Knebel        | Lausanne University Hospital, Lausanne, Switzerland | Performed statistical analysis                                        |
| Bruno Bartolini            | Lausanne University Hospital, Lausanne, Switzerland | Major role in acquisition of data                                     |
| Christoph C Kurmann         | University Hospital of Bern, Bern, Switzerland | Major role in acquisition of data                                     |
| Francesco Puccinelli       | Lausanne University Hospital, Lausanne, Switzerland | Major role in acquisition of data                                     |
| Pascal J Mosimann          | University Hospital of Bern, Bern, Switzerland | Major role in acquisition of data                                     |
| Christophe Bonvin          | Sion Hospital, Sion, Switzerland     | Major role in acquisition of data                                     |
| Marcel Arnold              | University Hospital of Bern, Bern, Switzerland | Major role in acquisition of data                                     |
| Julien Niederhäuser        | Nyon Regional Hospital, Nyon, Switzerland | Major role in acquisition of data                                     |
| Ashraf Eskandari           | Lausanne University Hospital, Lausanne, Switzerland | Interpreted the data                                                 |
| Pasquale Mordasini         | University Hospital of Bern, Bern, Switzerland | Major role in acquisition of data                                     |
| Jan Gralla                 | University Hospital of Bern, Bern, Switzerland | Major role in acquisition of data; study design                      |
| Urs Fischer                | University Hospital of Bern, Bern, Switzerland | Design and conceptualized study; data analysis; drafted the manuscript for intellectual content |
| Guillaume Saliou            | Lausanne University Hospital, Lausanne, Switzerland | Design and conceptualized study; data analysis; drafted the manuscript for intellectual content |
References:

1. Akerstedt T. [Increased risk of accidents during night shift. An underestimated problem are fatigue-induced accidents]. Lakartidningen 1995;92:2103-2104.

2. Akerstedt T. Shift work and disturbed sleep/wakefulness. Sleep Med Rev 1998;2:117-128.

3. Smith L, Folkard S, Poole CJ. Increased injuries on night shift. Lancet 1994;344:1137-1139.

4. Hanecke K, Tiedemann S, Nachreiner F, Grzech-Sukalo H. Accident risk as a function of hour at work and time of day as determined from accident data and exposure models for the German working population. Scand J Work Environ Health 1998;24 Suppl 3:43-48.

5. Colquhoun WP. Shiftwork : problems and solutions. Frankfurt am Main ; New York: P. lang, 1996.

6. Mansukhani MP, Kolla BP, Surani S, Varon J, Ramar K. Sleep deprivation in resident physicians, work hour limitations, and related outcomes: a systematic review of the literature. Postgrad Med 2012;124:241-249.

7. Maingard J, Kok HK, Ranatunga D, et al. The future of interventional and neurointerventional radiology: learning lessons from the past. Br J Radiol 2017;90:20170473.

8. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.

9. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019-1030.

10. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285-2295.
11. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009-1018.

12. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-2306.

13. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1723-1731.

14. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018;378:11-21.

15. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med 2018;378:708-718.

16. Ganesh A, Goyal M. Thrombectomy for Acute Ischemic Stroke: Recent Insights and Future Directions. Curr Neurol Neurosci Rep 2018;18:59.

17. Hussain S, Fiorella D, Mocco J, et al. In defense of our patients. J Neurointerv Surg 2017;9:525-526.

18. Hopkins LN, Holmes DR, Jr. Public Health Urgency Created by the Success of Mechanical Thrombectomy Studies in Stroke. Circulation 2017;135:1188-1190.

19. Gates M, Wingert A, Featherstone R, Samuels C, Simon C, Dyson MP. Impact of fatigue and insufficient sleep on physician and patient outcomes: a systematic review. BMJ Open 2018;8:e021967.

20. Almallouhi E, Al Kasab S, Harvey JB, et al. Impact of Treatment Time on the Long-Term Outcome of Stroke Patients Treated With Mechanical Thrombectomy. J Stroke Cerebrovasc Dis 2019;28:185-190.
21. Adams HP, Jr., Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.

22. Zaidat OO, Yoo AJ, Khatri P, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 2013;44:2650-2663.

23. Chaisinanunkul N, Adeoye O, Lewis RJ, et al. Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale. Stroke 2015;46:2238-2243.

24. Dijkland SA, Voormolen DC, Venema E, et al. Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study. Stroke 2018;49:965-971.

25. Valavanis A, Remonda L, Gralla J. La neuroradiologie: une discipline sous-estimée. Schweiz Arzteztg 2017;98:1639–1640.

26. Turner M, Barber M, Dodds H, et al. Stroke patients admitted within normal working hours are more likely to achieve process standards and to have better outcomes. J Neurol Neurosurg Psychiatry 2016;87:138-143.

27. Eskesen TG, Peponis T, Saillant N, et al. Operating at night does not increase the risk of intraoperative adverse events. Am J Surg 2018;216:19-24.

28. Arsava EM, Vural A, Akpinar E, et al. The detrimental effect of aging on leptomeningeal collaterals in ischemic stroke. J Stroke Cerebrovasc Dis 2014;23:421-426.

29. Nannoni S, Sirimarco G, Cereda CW, et al. Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients. J Neurol 2019;266:582-588.

30. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004;43:18-24.
31. Dargazanli C, Consoli A, Barral M, et al. Impact of Modified TICI 3 versus Modified TICI 2b Reperfusion Score to Predict Good Outcome following Endovascular Therapy. AJNR Am J Neuroradiol 2017;38:90-96.

32. Baek JH, Kim BM, Heo JH, et al. Number of Stent Retriever Passes Associated With Futile Recanalization in Acute Stroke. Stroke 2018;49:2088-2095.

33. Ntaios G, Papavasileiou V, Michel P, Tatlisumak T, Strbian D. Predicting functional outcome and symptomatic intracranial hemorrhage in patients with acute ischemic stroke: a glimpse into the crystal ball? Stroke 2015;46:899-908.

34. Mpotsaris A, Kowoll A, Weber W, Kabbasch C, Weber A, Behme D. Endovascular stroke therapy at nighttime and on weekends-as fast and effective as during normal business hours? J Vasc Interv Neurol 2015;8:39-45.

35. Hinsenveld WH, de Ridder IR, van Oostenbrugge RJ, et al. Workflow Intervals of Endovascular Acute Stroke Therapy During On- Versus Off-Hours: The MR CLEAN Registry. Stroke 2019;50:2842-2850.

36. Reinberg A, Vieux N, Andlauer P, Permanent Commission and International Association on Occupational Health. Scientific Committee on Shift Work. Night and shift work: biological and social aspects: proceedings of the Fifth International Symposium on Night and Shift Work: Scientific Committee on Shift Work of the Permanent Commission and International Association on Occupational Health (PCIAOH) Rouen, 12-16 May 1980, 1st ed. Oxford ; New York: Pergamon Press, 1981.
Figure 1. Analysis of the Primary Endpoint.

The forest plot shows the effect size in the primary endpoint (common odds ratio for improvement on the modified Rankin scale at 90 days, analyzed according to ordinal logistic regression and adjusted for age, symptom onset-to-EVT start time, age, National Institutes of Health Stroke Scale score, modified treatment in cerebral ischemia score, and pre-stroke modified Rankin Scale score) across all EVT start time cohorts.

There are significant differences in the morning cohorts at 08:00-10:20 and 10:20-11:34 suggesting better functional outcome at three months as well as in the end-of-workday cohorts at 15:55-17:15 and 18:55-20:55 suggesting poorer functional outcome at three months.
Figure 2. Scores on the utility-weighted modified Rankin Scale at 90 days for each stroke center as a function of endovascular therapy start time.

Data are organized into twelve equally-sized cohorts over 24 hours starting at 8:00. Higher scores indicated better functional outcome. Green shading corresponds to cohorts with favorable functional outcome at three months, while red shading corresponds to cohorts with poorer functional outcome at three months.
Figure 3. Shift schedules for physicians in interventional neuroradiology (INR), stroke unit (SU) and emergency neurology (EN).

Data are organized into twelve equally sized cohorts over 24 hours starting at 8:00. Green shading corresponds to cohorts with favorable functional outcome at three months, while red shading corresponds to cohorts with poorer functional outcome at three months.
Table 1: Patient characteristics and cardiovascular risk factors

|                        | Total (n=127) | 08:00-10:20 (n=127) | 10:20-11:34 (n=127) | 11:34-12:40 (n=127) | 12:40-13:37 (n=127) | 13:37-14:41 (n=127) | 14:41-15:55 (n=127) | 15:55-17:15 (n=127) | 17:15-18:55 (n=127) | 18:55-20:55 (n=127) | 20:55-22:57 (n=127) | 22:57-02:07 (n=127) | 02:07-07:58 (n=131) |
|------------------------|--------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| **Age, years**         | 71.1 (62.4-82.0) | 67.6 (57.7-78.7)   | 70.8 (62.8-81.4)   | 73.6 (66.3-82.1)   | 71.1 (62.3-82.1)   | 75.0 (69.4-85.7)   | 72.7 (65.0-82.1)   | 70.9 (62.4-82.1)   | 70.4 (60.6-83.0)   | 70.2 (59.2-81.1)   | 69.9 (59.9-81.2)   | 72.2 (63.7-81.7)   | 68.9 (60.1-79.2)   |
| **Female sex**         | 794/1527 (52.0) | 72 (56.7)           | 75 (59.5)           | 62 (50.4)           | 62 (48.8)           | 58 (45.7)           | 57 (44.9)           | 60 (47.2)           | 69 (54.3)           | 68 (53.5)           | 61 (48.0)           | 70 (55.1)           | 78 (59.5)           |
| **Atrial fibrillation**| 630/1398 (45.1) | 40 (33.6)           | 46 (39.0)           | 51 (43.6)           | 59 (49.6)           | 65 (54.2)           | 60 (52.2)           | 46 (40.7)           | 54 (46.6)           | 49 (43.4)           | 48 (43.2)           | 57 (49.1)           | 55 (45.5)           |
| **Smoking**            | 413/1500 (27.5) | 38 (30.2)           | 34 (27.0)           | 31 (24.6)           | 32 (25.6)           | 31 (24.8)           | 33 (27.5)           | 38 (30.9)           | 30 (24.0)           | 35 (27.8)           | 34 (27.4)           | 40 (31.8)           | 37 (28.9)           |
| **Diabetes**           | 298/1506 (19.8) | 22 (17.5)           | 30 (23.8)           | 21 (16.9)           | 16 (12.8)           | 23 (18.3)           | 26 (20.6)           | 28 (22.6)           | 26 (20.8)           | 30 (24.2)           | 30 (23.8)           | 23 (18.3)           | 23 (18.0)           |
| **Hyperlipidemia**     | 1025/1515 (67.7) | 86 (67.7)           | 82 (65.1)           | 95 (74.8)           | 82 (65.1)           | 92 (73.0)           | 83 (67.5)           | 84 (67.2)           | 85 (66.9)           | 84 (66.7)           | 72 (57.6)           | 86 (67.7)           | 94 (72.3)           |
| **Hypertension**       | 1153/1542 (74.7) | 83 (66.4)           | 88 (67.7)           | 108 (82.4)          | 96 (73.3)           | 103 (82.7)          | 100 (78.7)          | 99 (76.7)           | 96 (73.9)           | 93 (72.7)           | 93 (73.2)           | 101 (79.5)          | 89 (69.5)           |

Data are mean (IQR) or n (%). a P value = 0.002, calculated using one-way ANOVA. b P value = 0.025, calculated using one-way ANOVA.
| Table 2: Stroke characteristics |
|--------------------------------|
| **Total** | 14.8 (9.0-20.0) | 14.4 (8.0-19.0) | 13.1 (7.0-17.0) | 16.0 (10.5-20.0) | 14.7 (9.0-21.0) | 15.5 (10.0-21.0) | 13.4 (7.0-19.0) | 15.0 (9.0-19.0) | 14.7 (8.5-19.5) | 15.0 (8.0-19.0) | 15.1 (9.0-19.0) | 14.8 (8.0-19.0) | 16.3 (11.0-19.0) | **P value** |
| 08:00-10:20 (n=127) | 10:20-11:34 (n=127) | 11:34-12:40 (n=127) | 12:40-13:37 (n=127) | 13:37-14:41 (n=127) | 14:41-15:55 (n=127) | 15:55-17:15 (n=127) | 17:15-18:55 (n=127) | 18:55-20:55 (n=127) | 20:55-22:57 (n=127) | 22:57-02:07 (n=127) | 02:07-07:58 (n=131) | 0.051 |
| NIHSS at admission* | 7.8 (7-10) | 8 (7-9) | 7.8 (6-10) | 8.2 (7-10) | 8 (7-9) | 7.9 (7-10) | 7.9 (6-10) | 7.8 (7-9) | 7.9 (7-10) | 7.6 (7-9) | 7.9 (7-9) | 7.2 (6-9) | 0.400 |
| ASPECTSb | 792 (53.8) | 60 (59.0) | 49 (40.8) | 62 (51.2) | 73 (58.4) | 67 (55.4) | 71 (57.3) | 76 (60.3) | 75 (60.5) | 68 (54.4) | 59 (48.0) | 75 (62.5) | 57 (45.2) | 0.012 |
| i.v. t-PAc | TOASTd | 0.197 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 0-2 | 1349 (89.5) | 118 (94.4) | 109 (87.9) | 111 (87.4) | 110 (88.0) | 109 (88.6) | 109 (88.6) | 111 (89.5) | 113 (89.7) | 117 (92.9) | 109 (88.6) | 109 (88.6) | 115 (89.8) | 115 (89.8) |
| 0-2 | 0.833 |
| 3-5 | 158 (10.6) | 7 (5.6) | 15 (12.1) | 16 (12.6) | 15 (12.0) | 14 (11.4) | 14 (11.4) | 13 (10.5) | 13 (10.3) | 9 (7.1) | 15 (12.1) | 15 (11.4) | 14 (11.4) | 11 (9.9) |
| uw-mRSd | 0.833 |
| 0.004 |
| Onset-to-EVT start time- (mins) | 305 (178-350) | 306 (152-435) | 335 (169-422) | 312 (178-330) | 282 (170-274) | 313 (192-323) | 312 (164-347) | 299 (166-357) | 288 (166-334) | 294 (184-324) | 266 (169-304) | 273 (200-314) | 376 (245-462) | 0.004 |
| Admission-to-EVT start time- (mins) | 102 (65-117) | 97 (62-103) | 96 (61-105) | 87 (58-113) | 85 (54-112) | 95 (54-117) | 98 (59-117) | 110 (67-115) | 110 (70-117) | 106 (73-119) | 93 (71-115) | 110 (64-133) | 133 (84-134) | 0.001 |

Data are mean (IQR) or n (%). EVT=endovascular therapy. *Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42. Scores increase as a function of neurological deficit. **Alberta Stroke Program Early CT Score (ASPECTS) ranging from 0 to 10. c Intravenous treatment with tissue plasminogen activator (t-PA) was used up to 4.5 hours after symptom onset. 1473 patients analyzed. d Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of subtypes of acute ischemic stroke are defined as: 1-Large-arteryatherosclerosis, 2-Cardioembolism, 3- Small-vessel occlusion, 4-Stroke of other determined etiology and 5-Stroke of undetermined etiology. 1505 patients analyzed. e Scores on the modified Rankin scale: 0- no symptoms, 1- no clinically significant disability, 2- slight disability, 3- moderate disability, 4- moderately severe disability, 5- severe disability, 6- death. 1498 patients analyzed. f Score on utility-weighted modified Rankin scale (uw-mRS) ranges from 0; death to 10; no symptoms or disability. g EVT=endovascular therapy. h The P value was calculated using χ2-squared. i The P value was calculated using a one-way ANOVA.
Table 3: Occlusion site

|                  | Total  | 08:00-10:20 (n=127) | 10:20-11:34 (n=127) | 11:34-12:40 (n=127) | 12:40-13:37 (n=127) | 13:37-14:41 (n=127) | 14:41-15:55 (n=127) | 15:55-17:15 (n=127) | 17:15-18:55 (n=127) | 18:55-20:55 (n=127) | 20:55-22:57 (n=127) | 22:57-02:07 (n=127) | 02:07-07:58 (n=131) |
|------------------|--------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
| **Vertebral artery** | 18 (1.2) | 1 (0.8)              | 0 (0)               | 2 (1.7)             | 1 (0.8)             | 1 (0.9)             | 0 (0)               | 5 (4.3)             | 2 (1.6)             | 1 (0.8)             | 1 (0.8)             | 2 (1.7)             | 2 (1.7)             |
| **Basilar artery**  | 21 (1.5) | 2 (1.6)              | 1 (0.8)             | 1 (0.8)             | 3 (2.5)             | 2 (1.7)             | 0 (0)               | 2 (1.7)             | 1 (0.8)             | 3 (2.5)             | 2 (1.7)             | 3 (2.5)             | 1 (2.5)             |
| **Intercranial internal carotid artery** | 319 (22.1) | 23 (18.9)            | 26 (21.3)            | 25 (20.8)           | 29 (23.8)           | 29 (24.8)           | 21 (18.6)           | 19 (16.4)           | 26 (21.0)           | 34 (27.9)           | 30 (24.8)           | 23 (19.2)           | 34 (27.6)           |
| **First segment of middle cerebral artery** | 679 (47.1) | 61 (50.0)            | 58 (47.5)            | 62 (51.7)           | 55 (45.1)           | 56 (47.9)           | 56 (49.6)           | 55 (47.4)           | 68 (54.8)           | 54 (44.3)           | 59 (48.8)           | 51 (42.5)           | 44 (35.8)           |
| **Second segment of middle cerebral artery** | 272 (18.9) | 24 (19.7)            | 28 (23.0)            | 24 (20.0)           | 23 (18.9)           | 23 (19.7)           | 18 (15.9)           | 30 (25.9)           | 16 (12.9)           | 19 (15.6)           | 18 (14.9)           | 26 (21.7)           | 23 (18.7)           |
| **Third segment of middle cerebral artery** | 14 (1.0) | 1 (0.8)              | 1 (0.8)              | 1 (0.8)             | 0 (0)               | 2 (1.8)             | 0 (0)               | 2 (1.6)             | 2 (1.6)             | 2 (1.7)             | 1 (0.8)             | 1 (0.8)             |
| **Fourth segment of middle cerebral artery** | 1 (0.1) | 0 (0)                | 0 (0)                | 0 (0)               | 1 (0.9)             | 0 (0)               | 0 (0)               | 0 (0)               | 0 (0)               | 0 (0)               | 0 (0)               | 0 (0)               |
| **First segment of anterior cerebral artery** | 4 (0.3)  | 0 (0)                | 1 (0.8)              | 0 (0)               | 0 (0)               | 0 (0)               | 0 (0)               | 1 (0.8)             | 2 (1.6)             | 0 (0)               | 0 (0)               | 0 (0)               |
| **Second segment of anterior cerebral artery** | 4 (0.3)  | 0 (0)                | 0 (0)                | 0 (0)               | 0 (0)               | 1 (0.9)             | 0 (0)               | 1 (0.8)             | 0 (0)               | 0 (0)               | 1 (0.8)             | 1 (0.8)             |
| **First segment of posterior cerebral artery** | 104 (7.2) | 10 (8.2)             | 6 (4.9)              | 5 (4.2)             | 18 (2.8)            | 4 (3.4)             | 12 (4.1)            | 5 (4.3)             | 7 (5.6)             | 7 (5.7)             | 9 (7.4)             | 11 (9.2)            | 16 (13.0)           |
| **Second segment of posterior cerebral artery** | 6 (0.4)  | 0 (0)                | 1 (0.8)              | 0 (0)               | 0 (0)               | 1 (0.9)             | 1 (0.9)             | 0 (0)               | 0 (0)               | 0 (0)               | 2 (1.7)             | 1 (0.8)             |

Data are n (%). 1442 patients analyzed. *P value of 0.51 was calculated using $\chi^2$-squared. *Patients who had occlusion of intracranial internal carotid artery (carotid terminus) may have also had thrombus extension into the first segment of either the anterior and/or the middle cerebral artery.
Table 4: Unadjusted and adjusted association between EVT start time and long-term neurological outcome

| EVT start time | Modified Rankin Scale score at 90 days\(^a\) | Utility-weighted Modified Rankin Scale score at 90 days\(^b\) | Unadjusted Odds Ratio (95% CI) | Adjusted Odds Ratio (95% CI) | Mortality at 90 days | Adjusted Odds Ratio (95% CI) |
|----------------|---------------------------------------------|--------------------------------------------------------|-------------------------------|-------------------------------|-------------------|-------------------------------|
| 08:00-10:20 (n=127) | 15 (12.0) 32 (25.6) 35 (28.0) 13 (10.4) 9 (7.2) 5 (4.0) 16 (12.8) | 6.6 (6.5-9.1) p<0.001 | 0.51 (0.37-0.70) p<0.001 | 0.53 (0.38-0.75) p<0.001 | 0.52 (0.28-0.90) p=0.228 |
| 10:20-11:34 (n=127) | 20 (16.5) 25 (20.7) 20 (16.5) 13 (10.4) 16 (13.2) 7 (5.8) 19 (15.8) | 6.0 (3.3-9.1) p=0.008 | 0.63 (0.46-0.88) p=0.006 | 0.62 (0.44-0.87) p=0.006 | 0.71 (0.40-1.20) p=0.223 |
| 11:34-12:40 (n=127) | 14 (11.5) 18 (14.8) 18 (14.8) 23 (18.9) 13 (10.7) 6 (4.8) 30 (24.5) | 5.2 (0.0-9.1) p=0.709 | 1.03 (0.74-1.43) p=0.853 | 0.76 (0.54-1.07) p=0.123 | 0.86 (0.52-1.37) p=0.334 |
| 12:40-13:37 (n=127) | 10 (8.4) 21 (17.7) 21 (17.7) 16 (13.5) 19 (16.0) 6 (5.0) 26 (21.8) | 5.2 (0.0-9.1) p=0.677 | 1.02 (0.73-1.42) p=0.919 | 1.01 (0.71-1.43) p=0.950 | 0.93 (0.55-1.51) p=0.773 |
| 13:37-14:41 (n=127) | 13 (10.8) 19 (15.4) 17 (14.2) 23 (19.2) 9 (7.5) 10 (8.3) 29 (24.2) | 5.1 (0.0-9.1) p=0.862 | 1.08 (0.77-1.50) p=0.656 | 0.93 (0.65-1.32) p=0.675 | 0.83 (0.50-1.35) p=0.471 |
| 14:41-15:55 (n=127) | 12 (10.1) 19 (16.0) 26 (21.9) 23 (19.3) 8 (6.7) 5 (4.2) 26 (21.9) | 5.6 (0.0-9.1) p=0.353 | 0.87 (0.62-1.21) p=0.407 | 1.12 (0.78-1.59) p=0.349 | 1.06 (0.63-1.73) p=0.825 |
| 15:55-17:15 (n=127) | 11 (9.2) 16 (13.3) 20 (16.7) 10 (8.3) 16 (13.3) 8 (6.7) 39 (32.5) | 4.4 (0.0-7.6) p=0.017 | 1.46 (1.05-2.05) p=0.025 | 1.47 (1.03-2.09) p=0.034 | 1.78 (1.21-2.79) p=0.013 |
| 17:15-18:55 (n=127) | 12 (9.8) 19 (15.5) 23 (18.7) 17 (13.8) 12 (9.8) 8 (6.5) 32 (26.0) | 5.0 (0.0-8.4) p<0.001 | 1.09 (0.79-1.52) p=0.590 | 1.09 (0.77-1.54) p=0.629 | 1.20 (0.74-1.91) p=0.447 |
| 18:55-20:55 (n=127) | 9 (7.8) 13 (11.2) 23 (19.8) 12 (10.3) 18 (15.5) 9 (7.8) 32 (27.6) | 4.5 (0.0-7.6) p=0.086 | 1.42 (1.01-1.99) p=0.042 | 1.49 (1.03-2.15) p=0.033 | 1.08 (0.65-1.73) p=0.773 |
| 20:55-22:57 (n=127) | 11 (8.9) 22 (17.9) 17 (13.8) 19 (15.5) 20 (16.3) 6 (4.9) 28 (22.8) | 5.1 (0.9-9.1) p=0.712 | 1.06 (0.76-1.47) p=0.736 | 1.24 (0.87-1.77) p=0.226 | 1.04 (0.62-1.68) p=0.879 |
| 22:57-02:07 (n=127) | 10 (8.5) 19 (16.1) 23 (19.5) 14 (11.9) 14 (11.9) 6 (5.1) 32 (27.1) | 4.9 (0.0-7.6) p=0.557 | 1.12 (0.80-1.57) p=0.495 | 1.24 (0.86-1.78) p=0.243 | 1.28 (0.78-2.05) p=0.312 |
| 02:07-07:58 (n=131) | 8 (6.7) 15 (12.5) 24 (20.0) 19 (15.8) 16 (13.3) 8 (6.7) 30 (25.0) | 4.8 (0.0-7.6) p=0.245 | 1.28 (0.92-1.78) p=0.152 | 1.15 (0.80-1.65) p=0.453 | 1.02 (0.61-1.64) p=0.947 |

Data are mean (IQR) or n (%). \(^a\) Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death. Distribution of scores at 90 days for EVT start times in the overall trial population. \(^b\) The utility-weighted modified Rankin scale ranges from 0 (death) to 10 (no symptoms or disability). \(^c\) The measurement of effect was a cumulative logistic-regression odds ratio (shift analysis). \(^d\) Controlling for age, symptom onset-to-EVT start time, age, National Institutes of Health Stroke Scale score, modified treatment in cerebral ischemia score, and pre-stroke modified Rankin Scale score.
| mTICI<sup>a</sup> | Total | 08:00-10:20 (n=127) | 10:20-11:34 (n=127) | 11:34-12:40 (n=127) | 12:40-13:37 (n=127) | 13:37-14:41 (n=127) | 14:41-15:55 (n=127) | 15:55-17:15 (n=127) | 17:15-18:55 (n=127) | 18:55-20:55 (n=127) | 20:55-22:57 (n=127) | 22:57-02:07 (n=127) | 02:07-07:58 (n=131) | P value |
|----------------|--------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------|
| 3              | 734/1526 (48.1) | 51 (40.2) | 62 (48.8) | 66 (52.0) | 62 (48.8) | 61 (48.0) | 60 (48.0) | 62 (48.8) | 55 (43.3) | 58 (45.7) | 72 (56.7) | 55 (43.3) | 70 (53.4) | 0.0682 |
| 2b             | 528/1526 (34.6) | 58 (45.7) | 43 (33.9) | 37 (29.1) | 37 (29.1) | 45 (35.4) | 50 (40.0) | 41 (32.3) | 46 (36.2) | 37 (29.1) | 36 (28.4) | 52 (40.9) | 38 (29.0) |         |
| 0-2a           | 264/1526 (17.3) | 18 (14.2) | 22 (17.3) | 24 (18.9) | 20 (15.8) | 21 (16.5) | 15 (12.0) | 24 (18.9) | 26 (20.5) | 32 (25.2) | 19 (15.0) | 20 (15.8) | 23 (17.6) |         |
| sICH<sup>b</sup> | 118/1476 (8.0) | 5 (4.1) | 10 (7.9) | 9 (7.3) | 8 (6.7) | 10 (8.3) | 9 (7.3) | 13 (10.5) | 7 (5.6) | 9 (7.6) | 10 (8.2) | 10 (8.1) | 18 (14.3) | 0.374   |
| EVT start-to-recanalization time (min)<sup>c</sup> | 58.0 (29-75) | 56.1 (25-80) | 59.9 (31-75) | 65.9 (30-90) | 60 (34-72) | 57.7 (31-74) | 55.4 (30-68) | 58.9 (27-81) | 52.0 (29-67) | 52.0 (29-67) | 50.4 (25-65) | 59.7 (28-80) | 57.8 (30-86) | 0.282   |

Data are mean (IQR) or n (%). <sup>a</sup> Modified Thrombolysis in Cerebral Ischemia (mTICI) score: 2b or 3 indicates successful reperfusion. <sup>b</sup> Symptomatic intercranial hemorrhage (sICH). <sup>c</sup> EVT=endovascular therapy.
Association of Time of Day When Endovascular Therapy for Stroke Starts and Functional Outcome

Steven D Hajdu, Johannes Kaesmacher, Prof Patrik Michel, et al.

Neurology published online January 4, 2021
DOI 10.1212/WNL.0000000000011449

This information is current as of January 4, 2021